| __timestamp | Amgen Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 4422000000 | 3932000000 |
| Thursday, January 1, 2015 | 4227000000 | 3909000000 |
| Friday, January 1, 2016 | 4162000000 | 4946000000 |
| Sunday, January 1, 2017 | 4069000000 | 6066000000 |
| Monday, January 1, 2018 | 4101000000 | 6547000000 |
| Tuesday, January 1, 2019 | 4356000000 | 8078000000 |
| Wednesday, January 1, 2020 | 6159000000 | 11773000000 |
| Friday, January 1, 2021 | 6454000000 | 9940000000 |
| Saturday, January 1, 2022 | 6406000000 | 10137000000 |
| Sunday, January 1, 2023 | 8415000000 | 10693000000 |
| Monday, January 1, 2024 | 12858000000 | 0 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. Over the past decade, Amgen Inc. and Bristol-Myers Squibb Company have demonstrated contrasting trends in their cost of revenue. From 2014 to 2023, Amgen's cost of revenue increased by approximately 90%, peaking in 2023. In contrast, Bristol-Myers Squibb saw a staggering 172% rise, with a notable surge in 2020. This divergence highlights Bristol-Myers Squibb's aggressive expansion and investment strategies, while Amgen maintained a more conservative growth trajectory. By 2023, Bristol-Myers Squibb's cost of revenue was about 27% higher than Amgen's, reflecting its larger scale of operations. These insights underscore the strategic choices each company has made in navigating the competitive landscape, offering a fascinating glimpse into their financial stewardship.
Eli Lilly and Company vs Bristol-Myers Squibb Company: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down AstraZeneca PLC and Bristol-Myers Squibb Company's Expenses
Cost Insights: Breaking Down Amgen Inc. and Regeneron Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Grifols, S.A.
Amgen Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Amgen Inc. and Amphastar Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Bristol-Myers Squibb Company vs Wave Life Sciences Ltd.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Viridian Therapeutics, Inc.